《新股表现》健倍苗苗(02161.HK)暗盘高开近17%报1.4元
根据辉立交易平台显示,明天挂牌的健倍苗苗(02161.HK)暗盘高开近17%报1.4元,高低见1.47元/1.33元,现造1.44元,较上市价1.2元,升20%,成交100万股。
由雅各臣(02633.HK)分拆上市的健倍苗苗,为总部设於香港的领先品牌医疗保健品推广及分销公司,其产品据点遍及大中华、东南亚和其他选定国家。是次上市以每股1.2元合共发售4,468.6万股,公开发售获约21.5倍超购,认购一手中签率仅8%,料集资净额约1,060万元,主要用於为品牌中药组合开发与品牌管理提供资金,以及用作发展第三方品牌产品组合增长策略一部分,为从第三方品牌拥有人获得更多分销权的付款提供资金等。上市独家保荐人为银河国际证券(香港)。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.